Chris Wiwi, PhD
Dispatch Bio
Chris Wiwi is Chief Technical Officer at Dispatch Bio, where he leads CMC and Technical Operations supporting clinical development of a next-generation oncology platform targeting solid tumors. Dispatch’s DISP-10 and DISP-11 programs are entering early-phase clinical studies in the U.S. and China.
Chris is a seasoned cell therapy executive with deep expertise in CMC strategy, development, and global commercialization. He began his career at Celgene, building Analytical R&D within the Cellular Therapeutics division and driving programs from research through IND and clinical manufacturing, including Abecma, the first-in-class anti-BCMA CAR T therapy for multiple myeloma.
He later led CMC for Abecma, overseeing global clinical expansion, registrational manufacturing, and regulatory approvals across the U.S., Europe, Switzerland, and Canada, followed by U.S. commercialization. He subsequently led technical commercialization for Abecma and Breyanzi, defining global supply strategy and end-to-end lifecycle execution.
Before joining Dispatch, Chris built and led Technical Operations at Mnemo Therapeutics. Earlier in his career, he held bioanalytical leadership roles at Merck and Schering-Plough and completed postdoctoral research at Johnson & Johnson. He holds a Ph.D. in Cellular and Molecular Biology from Boston University and a B.S. from the University of Notre Dame.
Chris is a seasoned cell therapy executive with deep expertise in CMC strategy, development, and global commercialization. He began his career at Celgene, building Analytical R&D within the Cellular Therapeutics division and driving programs from research through IND and clinical manufacturing, including Abecma, the first-in-class anti-BCMA CAR T therapy for multiple myeloma.
He later led CMC for Abecma, overseeing global clinical expansion, registrational manufacturing, and regulatory approvals across the U.S., Europe, Switzerland, and Canada, followed by U.S. commercialization. He subsequently led technical commercialization for Abecma and Breyanzi, defining global supply strategy and end-to-end lifecycle execution.
Before joining Dispatch, Chris built and led Technical Operations at Mnemo Therapeutics. Earlier in his career, he held bioanalytical leadership roles at Merck and Schering-Plough and completed postdoctoral research at Johnson & Johnson. He holds a Ph.D. in Cellular and Molecular Biology from Boston University and a B.S. from the University of Notre Dame.
